Biontech SE revenue

Biontech SE's revenue was $3.24bn in fiscal 2025, up 9.0% on the year before. Since fiscal 2017 ($69.6m) it has grown at a compound 61.6% a year.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biontech SE: revenue history, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0.1	0.2	0.1	0.6	22.5	18.2	4.1	3.0	3.2
Growth on the year before	—	+116.6%	−19.4%	+352.7%	+>999%	−18.8%	−77.3%	−27.9%	+9.0%
Gross profit	0.1	0.1	0.1	0.5	19.0	15.1	3.5	2.4	2.5
Gross margin	84.9%	89.3%	84.0%	87.7%	84.7%	82.7%	84.3%	80.3%	77.6%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Biontech SE	$3.24bn	9.0%	—
United Therapeutics Corp	$3.15bn	2.5%	14.3%
Biomarin Pharmaceutical Inc	$3.41bn	11.2%	15.1%
Neurocrine Biosciences Inc	$3.70bn	38.0%	27.5%
Natera, Inc.	$2.71bn	37.8%	42.7%
Argenx SE	$4.15bn	89.9%	—

Compare with peers

Head to head: BNTX vs UTHR BMRN vs BNTX BNTX vs NBIX BNTX vs NTRA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biontech SE's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biontech SE.